The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin

Russell P. Rother(Alexion Pharmaceuticals (United States)), Mark T. Gladwin(University of Maryland, Baltimore), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Leonard Bell(Alexion Pharmaceuticals (United States))
JAMA
April 6, 2005
10.1001/jama.293.13.1653
Cited by 1,542

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k